Changing paradigms in the treatment of multiple myeloma

Haematologica

Volumn 94, Issue 2, 2009, Pages 163-166

  Bladé, Joan ^a   Rosiñol, Laura ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER REGISTRY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; COMORBIDITY; EDITORIAL; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; KIDNEY FAILURE; LEUKEMIA RELAPSE; MULTIPLE MYELOMA;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PATIENT SELECTION; SALVAGE THERAPY;

EID: 59449090984     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.2008.002766     Document Type: Editorial

References (30)

1. Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008;20:697-704.
2. Harousseau JL. Role of stem cell transplantation in multiple myeloma. Hematol Oncol Clin North Am 2007;21:1157-74.
3. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed myeloma: a clinical trial coordinated by the Eastern Cooperative Group. J Clin Oncol 2006;24:431-6.
4. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006;91:1498-505.
5. Rosiñol L, Oriol A, Mateos MV, Sureda A, García- Sánchez P, Gutiérrez N, et al. A phase II trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumour response kinetics. J Clin Oncol 2007;25:4452-8.
6. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62.
7. Cavo M, Patriarca F, Tachetti P, Galli M, Perrone G, Petrucci MT, et al. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) versus thalidomide- dexamethasone (TD) in preparation for autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2007;110:11 [Abstract 73].
8. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85.
9. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158-64.
10. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80.
11. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting in newly diagnosed myeloma. N Engl J Med 2007;356:1110-20.
12. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantatin versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591-3.
13. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyenet C, et al. Melphalan-Prednisone-Thalidomide (MPT) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007:110:31a [Abstract 75].
14. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
15. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 25:4459-65.
16. Ludwig H, Hajek R, Thotova E, Drach J, Adam Z, Labaret B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood prepublished online Oct. 27, 2008; doi: 10.1182/blood-2008-07-169565.
17. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-7.
18. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-84.
19. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:[Abstract 8504].
20. Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, et al. Thalidomide for the treatment of multiple myeloma: 10-years-later. Blood 2008;11:3968-77.
21. Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, et al. Escape of extramedullary disease to the thalidomide effect in multiple myeloma. Haematologica 2004;89:832-6.
22. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
23. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
24. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma. Combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
25. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.
26. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
27. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9.
28. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6.
29. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
30. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009;94.270-5.